Melissa K. Zochowski

Human papillomavirus vaccine intent and uptake among female college students

Abstract Objective: To examine human papillomavirus (HPV) vaccine intent and the effect of an educational intervention on vaccine uptake among female college students. Participants: Females aged 18 to 26 attending a university health service gynecology clinic (n = 256). Methods: Participants were randomized to receive either HPV-specific education with a mailed reminder or standard care. Predictors of HPV vaccine intent and uptake at 6 months following enrollment were identified. Results: At baseline, 41% intended to undergo HPV vaccination. Participants who were currently sexually active and lacked supplemental health insurance had decreased intent. Perceived parental approval regarding HPV vaccination, perceived vulnerability to HPV infection, and belief in health benefits of HPV vaccine were associated with increased intent. HPV vaccine uptake was low (5.5%) and did not differ by study group. However, baseline intent was significantly associated with HPV vaccine uptake. Conclusions: Interventions to increase HPV vaccine uptake in college students should address HPV-related beliefs and broader barriers to vaccination.

Economic Cost of Fecal Incontinence

BACKGROUND: Despite its prevalence and deleterious impact on patients and families, fecal incontinence remains an understudied condition. Few data are available on its economic burden in the United States. OBJECTIVE: The aim of this study was to quantify per patient annual economic costs associated with fecal incontinence. DESIGN: A mail survey of patients with fecal incontinence was conducted in 2010 to collect information on their sociodemographic characteristics, fecal incontinence symptoms, and utilization of medical and nonmedical resources for fecal incontinence. The analysis was conducted from a societal perspective and included both direct and indirect (ie, productivity loss) costs. Unit costs were determined based on standard Medicare reimbursement rates, national average wholesale prices of medications, and estimates from other relevant sources. All cost estimates were reported in 2010 US dollars. SETTINGS: This study was conducted at a single tertiary care institution. PATIENTS: The analysis included 332 adult patients who had fecal incontinence for more than a year with at least monthly leakage of solid, liquid, or mucous stool. MAIN OUTCOME MEASURES: The primary outcome measured was the per patient annual economic costs associated with fecal incontinence. RESULTS: The average annual total cost for fecal incontinence was

Receipt of prescription contraception by commercially insured women with chronic medical conditions.

4110 per person (median =

Nonhuman Primate Models Used to Study Pelvic Inflammatory Disease Caused by Chlamydia trachomatis

1594; interquartile range,

Women’s Health and the Affordable Care Act: High Hopes Versus Harsh Realities?

517–

Novel Genital Alphapapillomaviruses in Baboons (Papio hamadryas Anubis) With Cervical Dysplasia

5164). Of these costs, direct medical and nonmedical costs averaged

The Effects of a Single Cervical Inoculation of Chlamydia trachomatis on the Female Reproductive Tract of the Baboon (Papio anubis)

2353 (median,

Human Papillomavirus Vaccine Uptake After a Tailored, Online Educational Intervention for Female University Students: A Randomized Controlled Trial

1176; interquartile range,

Treatment of early pregnancy failure: does induced abortion training affect later practices?

294–

Beyond usual care: the economic consequences of expanding treatment options in early pregnancy loss

2438) and